Industry criticizes India's reliance on drug importers for ADR-related action
This article was originally published in SRA
Executive Summary
India has underscored the significance of proactive reporting by drug importers of adverse reaction-related "administrative action" of foreign regulators as part of the country's efforts to improve regulatory compliance1.
You may also be interested in...
India Specifies Requirements For Pharmacovigilance System Master File, Qualified Person
The Indian government has borrowed some EU concepts while framing a pharmacovigilance guideline for marketing authorization holders. The guideline, effective January 2018, requires marketing authorization holders to maintain a pharmacovigilance system master file within India where the main pharmacovigilance activities take place, and to hire a pharmacovigilance qualified person to oversee the entire system.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet